GSK, mRNA and influenza vaccine
British drugmaker GSK moves mRNA flu vaccine to late-stage trials
(Reuters) -British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development.
GSK's mRNA flu vaccine finally overcomes tricky B strains in phase 2 trial
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has
After positive midstage trial, GSK moves mRNA flu vaccine to late-stage trials
British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal
GSK reports positive results from mRNA flu vaccine trial
GSK announced promising results from its phase two clinical trial for an mRNA-based seasonal flu vaccine on Thursday.
GSK moves mRNA flu vaccine to late-stage trials following positive outcomes
GSK bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials.
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024,
GSK reports positive interim data from mRNA influenza vaccine trial
"GSK reports positive interim data from mRNA influenza vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on t
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...
Health.com on MSN8d
Guide to 2024 Fall Vaccines: When to Get Your COVID, Flu, and RSV Shots
Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...
New COVID vaccines may be coming to Australia. Here’s what to know about the JN.1 shots
In Australia, our process differs slightly and tends to take a little longer. The TGA’s website indicates applications for ...
Business Insider9d
EQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza ... key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is ...
Adult Vaccine Market Forecasts Report and Competitive Landscape 2024-2032 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL
Adult Vaccine Market Adult Vaccine Market Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Report, ...